Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target.

Nature reviews. Drug discovery - 1 Aug 2020

Mifflin Lauren, Ofengeim Dimitry, Yuan Junying

Abstract excerpt

Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is a key mediator of cell death and inflammation. The unique hydrophobic pocket in the allosteric regulatory domain of RIPK1 has enabled the development of highly selective small-molecule inhibitors of its kinase activity, which have demonstrated safety in preclinical models and clinical trials. Potential applications of these RIPK1 inhibitors for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Delivery Systems
Share to Mutation
Share to Protein Kinase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Receptor-Interacting Protein Serine-Threonine Kinases

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 32669658
DOI: 10.1038/s41573-020-0071-y
PMCID: PMC7362612

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target.PMID 32669658Read ↗

Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation.Semantic proximity Read ↗

Death-domain dimerization-mediated activation of RIPK1 controls necroptosis and RIPK1-dependent apoptosis.Semantic proximity Read ↗

New autoinflammatory disease caused by non-cleavable RIPK1 variants.Semantic proximity Read ↗

Primary immunodeficiency reveals importance of RIPK1.Semantic proximity Read ↗

RIPK1 Biallelic Activating Variants lead to Autoinflammatory Disease Driven by T cell DeathSemantic proximity Read ↗

[Autoinflammatory diseases associated with RIPK1 mutations: A review of the literature].Semantic proximity Read ↗

RIPK1 ubiquitination regulates its kinase-independent function in development and inflammation.Semantic proximity Read ↗

Ubiquitination of RIPK1 regulates its activation mediated by TNFR1 and TLRs signaling in distinct manners.Semantic proximity Read ↗

RIPK1 dephosphorylation and kinase activation by PPP1R3G/PP1γ promote apoptosis and necroptosis.Semantic proximity Read ↗

Neonatal onset inflammatory bowel disease and immunodeficiency due to compound heterozygous variants in RIPK1: Expanding the phenotypic spectrum and literature reviewSemantic proximity Read ↗

An unusual case of RIPK1-related immunodeficiency: The importance of a timely diagnosis for a novel clinical and therapeutic pattern.Semantic proximity Read ↗

K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.